MRNAModerna, Inc.

Nasdaq modernatx.com


$ 86.61 $ -7.56 (-8.03 %)    

Friday, 02-Aug-2024 15:59:59 EDT
QQQ $ 447.95 $ -3.89 (-0.86 %)
DIA $ 397.31 $ -5.92 (-1.47 %)
SPY $ 532.92 $ -10.09 (-1.86 %)
TLT $ 98.17 $ 2.86 (3 %)
GLD $ 225.36 $ -0.41 (-0.18 %)
$ 86.58
$ 92.36
$ 70.00 x 109
$ 86.71 x 100
$ 84.45 - $ 92.64
$ 62.55 - $ 170.47
18,591,903
na
36.16B
$ 0.37
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-01-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 02-23-2024 12-31-2023 10-K
4 11-03-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 02-24-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-03-2022 06-30-2022 10-Q
10 05-04-2022 03-31-2022 10-Q
11 02-25-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-26-2021 12-31-2020 10-K
16 10-30-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 11-06-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-13-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rbc-capital-maintains-outperform-on-moderna-lowers-price-target-to-125

RBC Capital analyst Luca Issi maintains Moderna (NASDAQ:MRNA) with a Outperform and lowers the price target from $160 to $125.

 moderna-stock-trading-lower-on-dismal-guidance-analysts-cuts-price-targets-noting-competitive-pressure-from-gsk-pfizer

Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down fro...

 goldman-sachs-maintains-buy-on-moderna-lowers-price-target-to-178

Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Buy and lowers the price target from $204 to $178.

 barclays-maintains-overweight-on-moderna-lowers-price-target-to-155

Barclays analyst Gena Wang maintains Moderna (NASDAQ:MRNA) with a Overweight and lowers the price target from $168 to $155.

 piper-sandler-reiterates-overweight-on-moderna-lowers-price-target-to-157

Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and lowers the price target from $2...

 cathie-woods-ark-adds-over-19m-worth-of-moderna-shares-after-thursdays-21-plunge-on-guidance-cut

Moderna's vaccine magic is slowly losing its charm, as evidenced by the warning the company issued on Thursday but Ark repo...

 us-stocks-close-lower-as-apple-amazon-report-earnings-greed-index-moves-to-fear-zone

The CNN Fear and Greed index fell to 39.6, signaling Fear in the market. Dow Jones dropped 495 points, Nasdaq down 2.3%, S&...

 needham-reiterates-hold-on-moderna

Needham analyst Joseph Stringer reiterates Moderna (NASDAQ:MRNA) with a Hold.

 stock-of-the-day-moderna-stock-plunges-breaking-key-support-levels-following-earnings-report

Shares of Moderna (MRNA) have broken an important support level. This means a new downtrend may be forming.

 moderna-stock-sinks-on-lowered-2024-outlook-cites-low-european-sales-competitive-rsv-vaccine-market

Moderna's stock drops after cutting 2024 sales forecast due to reduced COVID-19 vaccine demand. The company now expects net...

Core News & Articles

- Conference Call

 moderna-revises-its-2024-expected-net-product-sales-to-3b-35b-from-its-respiratory-franchise-compared-to-prior-guidance-of-4b

For the second half of the year, it expects a sales split of 40-50% in the third quarter with the balance in the fourth quarter...

Core News & Articles

Directors Robert Langer and Stephen Berenson will also retire from the Board.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION